Pharmacotherapy of obesity: targets and perspectives

Area of Science:

• Pharmacology and Drug Discovery
• Metabolic Diseases
• Obesity Pathophysiology

Background:

• The discovery of anti-obesity agents is a significant focus in pharmaceutical research.
• The field has progressed from identifying molecular targets to validating their therapeutic potential.
• Complex biological systems regulate energy intake and expenditure, necessitating a deep understanding of pathophysiology for effective obesity treatments.

Purpose of the Study:

• To review the current landscape of anti-obesity agent development.
• To highlight the shift from target identification to target validation in obesity drug discovery.
• To discuss the role of understanding complex energy balance mechanisms and human genetic obesity data in selecting successful drug candidates.

Main Methods:

• Literature review and synthesis of current research in obesity and drug discovery.
• Analysis of the transition from target identification to target validation strategies.
• Evaluation of insights gained from rodent models and monogenic human obesity studies.

Main Results:

• A substantial increase in potential molecular targets for anti-obesity drugs has been identified.
• The focus in drug discovery has shifted towards validating these targets.
• Rodent studies and human genetic data provide partial understanding, but clinical proof of concept for weight reduction is still evolving.

Conclusions:

• Understanding the complex pathophysiology of energy balance is crucial for developing effective anti-obesity therapies.
• While progress has been made, the most promising clinical approaches for significant weight reduction and associated health improvements are yet to be definitively established.
• Further research is needed to translate mechanistic insights into successful clinical treatments for obesity.